SIFI SpA

SIFI SpA Azienda italiana leader nell'EyeCare dal 1935 SIFI, la più importante azienda oftalmica italiana, opera nel settore della cura dell’occhio dal 1935.

La sua missione è quella di fornire agli oftalmologi e ai loro pazienti una vasta gamma di soluzioni terapeutiche alle patologie oculari più diffuse, producendo e commercializzando innovativi farmaci e dispositivi medici. Azienda con un business model integrato, dalla ricerca e sviluppo, alla produzione e commercializzazione sia in ambito farmaceutico che biomedicale, sostiene il proprio vantaggio

competitivo coniugando la ricerca e sviluppo interna, che negli ultimi anni ha generato oltre 60 brevetti a livello mondiale, con una consolidata rete internazionale di alleanze per lo sviluppo di nuovi prodotti e per la commercializzazione all’estero del suo ampio portafoglio. SIFI completa la sua offerta con nutraceutici, prodotti per l’igiene oculare e strumenti diagnostici, frutto del proprio know-how specifico nel settore. La sua storia di quasi ottant’anni è caratterizzata dal perseguimento dell’eccellenza e dall’elevato livello di servizio alla classe medica oftalmica, prevalentemente in Italia. Attualmente il Gruppo SIFI conta più di 360 dipendenti, di cui oltre 20 impegnati nell'area Ricerca e Sviluppo, e raggiunge un fatturato di circa 65 milioni di euro, investendo circa il 10% dei ricavi in R&D. Il Gruppo è strutturato in due aree di business – Pharma e Medtech – ed è presente in oltre 15 paesi del mondo, con filiali commerciali in Messico e Romania. SIFI, the leading Italian ophthalmic company, has been focused on Eye Care since its foundation in 1935. Our mission is to provide ophthalmologists and their patients with a wide range of therapeutic solutions to treat the most common eye diseases, by manufacturing and marketing innovative pharmaceuticals and medical devices. SIFI features an integrated business model, from research & development to manufacturing and commercialization both in the pharmaceutical and biomedical sectors. SIFI develops its competitive advantage through a combination of internal R&D, which has led to more than 60 patents in the last few years, and a strong international network of alliances to develop new products and to market its wide product portfolio overseas. Our offering is completed with ophthalmic nutraceuticals, cosmetics and diagnostic instruments, that leverage on our specialty know-how. SIFI’s 80-years history is distinguished with the pursuit of excellence and the highest level of educational service to the ophthalmic community, most notably in Italy. Currently the SIFI Group employs around 360 people – more than 20 in R&D - and has a turnover of about € 65 million. Each year SIFI invests approximately 10% of sales in R&D. The Group is organized into two business areas – Pharma and Medtech – and its products are sold in more than 15 countries worldwide, with commercial subsidiaries in Mexico and Romania.

01/08/2025
🔬 New scientific publication 🌟We are pleased to share that the study “Clinical Outcomes and Optical Bench Analysis of a ...
21/07/2025

🔬 New scientific publication 🌟
We are pleased to share that the study “Clinical Outcomes and Optical Bench Analysis of a Novel Enhanced Monofocal Intraocular Lens” by Giovanni Romualdi et al. has been published in Life (vol. 15, no. 6, 2025).

👁️ Study Objective
To evaluate the clinical performance of the new Evolux enhanced range of vision IOL compared to the traditional monofocal IOL Tecnis GCB00 (J&J), enhancing intermediate vision without compromising distance vision or inducing photic phenomena.

📊 Methodology
• Prospective, single-center, comparative clinical study on 100 eyes
• Two groups:
o bilateral implantation of Tecnis GCB00
o bilateral implantation of Evolux
• Evaluated parameters: visual acuity (distance and intermediate), refractive predictability, contrast sensitivity, optical quality, spectacle independence
• Supported by optical bench analysis

✅ Key Results
• Evolux provided significantly better uncorrected and distance-corrected intermediate visual acuity (UIVA LogMAR 0.10 vs 0.26, p < 0.001)
• Comparable distance vision in both groups
• No increase in halos or reduction in contrast sensitivity

🔍 Conclusion
The new Evolux IOL offers a significant improvement in intermediate vision without sacrificing distance vision, representing a meaningful advance in cataract surgery.

📌 Congratulations to Giovanni Romualdi, Matilde Buzzi, Pier G. Ruggeri, Federico Tommasi, Alessio Giorgetti, Stefano Cavalieri, and Rita Mencucci on this achievement—a further step toward enhancing patients’ everyday visual experience! 🎯

Purpose: A novel enhanced monofocal intraocular lens (IOL) has been developed to improve functional intermediate vision, maintaining a distance vision comparable to a standard monofocal lens and avoiding the drawbacks of multifocal IOLs. The aim of this study is to perform optical bench analysis and...

🎉 Major milestone in ophthalmology!SIFI has received reimbursement approval in Spain for AKANTIOR® (polihexanide 0.08%),...
14/07/2025

🎉 Major milestone in ophthalmology!
SIFI has received reimbursement approval in Spain for AKANTIOR® (polihexanide 0.08%), the first and only approved treatment for Acanthamoeba keratitis (AK) in adults and adolescents aged ≥12 years.

✅ Spain is the first country worldwide to approve price and reimbursement for AKANTIOR®.
✅ AKANTIOR® is already available in Germany since October 2024.
🗓 It will be fully reimbursed by the national healthcare system starting August 1, 2025.
💊 Phase 3 clinical trials show up to 85% resolution rate with standardized monotherapy.
👁️ Over 70 patients in Spain have already been treated under early access programs.
⚠️ Acanthamoeba keratitis is a rare, painful, and sight-threatening eye infection, often linked to contact lens use.

Discover more:
https://www.prnewswire.co.uk/news-releases/sifi-announces-reimbursement-approval-for-akantior-in-spain-302503874.html?tc=eml_cleartime

01/07/2025
🚨 SIFI at SICSSO 2025!SIFI will take part in the SICSSO Congress – The International Society of Cornea, Stem Cells and O...
09/06/2025

🚨 SIFI at SICSSO 2025!

SIFI will take part in the SICSSO Congress – The International Society of Cornea, Stem Cells and Ocular Surface, which will be held in Grosseto starting from June 12, 2025.

📍 Don't miss the Round Table session:
"Acanthamoeba Keratitis (AK): Tips from the Experts"
🗓 June 13 | 🕧 12:15 PM – 1:00 PM | 📌 Main Room

👉 A unique opportunity to delve into the diagnosis, treatment, and management of one of the most challenging corneal infections, together with top international experts.

📢 We look forward to seeing you there!

02/06/2025

How do you ensure rotational stability and patient satisfaction with toric IOLs?

Prof. Emilio Pedrotti (Italy) shares why the Mini WELL® Toric IOL from SIFI stands out—highlighting design features like the 4-loop haptics and precise spherical aberration management that drive consistent outcomes across all levels of astigmatism.

Watch his full perspective here and see how surgical precision meets patient-centered innovation.

Learn more: https://www.sifigroup.com/

🌍 SIFI is proud to be present at the 16th EUCORNEA Congress in Prague, taking place from May 23rd to 25th, 2025 at the C...
22/05/2025

🌍 SIFI is proud to be present at the 16th EUCORNEA Congress in Prague, taking place from May 23rd to 25th, 2025 at the Clarion Congress Hotel Prague.
📢 We warmly invite you to attend our symposium, organized in collaboration with Avanzanite Bioscience:
🔬 ODAK'S LEGACY: Advancing Diagnosis and Management of Acanthamoeba Keratitis
📅 Saturday, May 24th
🕓 16:15 – 17:00
📍 Location: Tycho/Kepler room - Clarion Congress Hotel

Join us as we explore the latest innovations and clinical insights in the diagnosis and treatment of this challenging corneal infection.
Looking forward to seeing you in Prague!

📢 SIFI receives Marketing Authorisation and Promising Innovative Medicine Designation for AKANTIOR® in the UKSIFI is ple...
19/05/2025

📢 SIFI receives Marketing Authorisation and Promising Innovative Medicine Designation for AKANTIOR® in the UK
SIFI is pleased to announce that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for AKANTIOR® (polihexanide 0.08%), confirming both its Orphan Drug Designation and New Active Substance status. In addition, AKANTIOR® received the Promising Innovative Medicine (PIM) Designation earlier this month.
🧪 With these authorisations, AKANTIOR® becomes the first and only approved treatment in the UK for Acanthamoeba keratitis, an ultra-rare, debilitating eye infection that can lead to blindness if left untreated.
📄 Read the full announcement here: https://www.prnewswire.co.uk/news-releases/sifi-receives-marketing-authorisation-and-promising-innovative-medicine-designation-for-akantior-in-the-uk-302458363.html?tc=eml_cleartime

🔹 SIFI at RCOphth Annual Congress 2025📍 Liverpool | 19–22 May | ACC Liverpool📌 Visit us at Stand 20We’re excited to join...
16/05/2025

🔹 SIFI at RCOphth Annual Congress 2025
📍 Liverpool | 19–22 May | ACC Liverpool
📌 Visit us at Stand 20
We’re excited to join the Royal College of Ophthalmologists Annual Congress! Come meet the SIFI team at Stand 20 to explore our latest innovations in eye care.
👁️ Don’t miss our symposium:
Acanthamoeba Keratitis: Science Over Guesswork
📅 Tuesday, 20 May
🕠 17:30–18:30 | Room 12
Join us for expert insights, clinical experiences, and engaging discussion.

🔵 SIFI changes its look, but not its vision.For 90 years, we have looked beyond the horizon of sight, standing alongside...
06/05/2025

🔵 SIFI changes its look, but not its vision.
For 90 years, we have looked beyond the horizon of sight, standing alongside ophthalmologists with innovative solutions, thanks to the dedication of extraordinary people whose talent and professionalism have built a legacy of expertise that still guides our mission to improve patients’ eye health.

Today, we celebrate a new chapter in our journey with a renewed visual identity.
👁 Our logo evolves while staying true to our essence.
✨ “Visionary Care”, our new payoff, encapsulates our pioneering vision, our patient-centric approach, and our commitment to an increasingly innovative future.
🚀 The new corporate image tells a story, a journey that today evolves through a refreshed identity, firmly rooted in the values that have always guided us.

This is much more than a rebranding:
it’s the expression of our mission to improve patients’ lives with tangible innovation, from daily care to revolutionary breakthroughs.

Excited to share the latest White Paper:"Well Fusion Optical System- The Innovative Alternative to Trifocals", author Pr...
30/04/2025

Excited to share the latest White Paper:
"Well Fusion Optical System- The Innovative Alternative to Trifocals", author Prof. Emilio Pedrotti, University of Verona, Italy.

This publication includes the direct comparison of bilateral implantation outcomes of Mini WELL and Mini WELL PROXA IOLs vs bilateral implantations of a trifocal IOL (Fine Vision POD F -BVI).

Key findings:
• both groups achieved very good visual acuities at all distances
• the defocus curve of WELL Fusion Optical System was smoother and showed continuous, uninterrupted, and better VA for intermediate and near distances (called “PROXA EFFECT”)
• WELL Fusion Optical System showed significant better results in terms of quality of vision in both objective and subjective tests compared to the trifocals group
• Patients implanted with WELL Fusion System experienced the highest grade of satisfaction at 3-months follow up, compared to the trifocal group
• Well Fusion Optical System might be a compelling alternative to trifocals in patients looking for full presbyopia correction without compromising the quality of vision

WELL

Article:

A comparison of bilateral implantation outcomes of Mini WELL® and Mini WELL PROXA® IOLs versus trifocal IOLs

12 months. Real-world results on EVOLUX IOL. Proven patient satisfaction.We’re excited to share our new white paper on t...
16/04/2025

12 months. Real-world results on EVOLUX IOL. Proven patient satisfaction.

We’re excited to share our new white paper on the:
Evolux- Enhanced Range of Vision Intraocular Lens

Dr. Dana Preoteasa, Onioptic Medical Hospital, Romania and Dr. Victor Caparas, Medical City Eye and Vision Institute, Philippines shared 12-month clinical follow-up data that highlight visual outcomes, spectacle independence, and patient-reported quality of life.

Key insights include:

• Excellent and stable intermediate and distance vision over 12 months
• Functional near vision
• Photic phenomena profile similar to a monofocal
• Enhanced continuous range of vision up to 2D
• High patient satisfaction and visual comfort in daily activities

Experts evaluate long term results, at 12 months, for EVOLUX®, SIFI's new enhanced range of vision IOL

Indirizzo

Via Ercole Patti, 36
Catania
95025

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando SIFI SpA pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a SIFI SpA:

Condividi